Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Open Access
- 1 July 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in CNS Drugs
- Vol. 29 (7), 565-575
- https://doi.org/10.1007/s40263-015-0261-z
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The selective sphingosine 1‐phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species‐specific effects on heart rateBritish Journal of Pharmacology, 2012
- Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple SclerosisPharmaceuticals, 2012
- Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patientsJournal of the Neurological Sciences, 2011
- Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosisAnnals of Neurology, 2011
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart RateOnline Journal of Public Health Informatics, 2004
- Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor SubtypesThe Journal of pharmacology and experimental therapeutics, 2004
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsJournal of Biological Chemistry, 2002